MHRA paediatric investigation plan

gadoquatrane (gadoquatrane)

MHRA paediatric investigation plan MHRA-101024-PIP01-23-M01 (update) · Modification

Key facts

PIP number MHRA-101024-PIP01-23-M01 (update)
Active substances gadoquatrane
Therapeutic areas Diagnostic
Conditions Diagnosis by evaluation of any known or suspected clinical condition with contrast enhanced magnetic resonance imaging
Decision PM: decision on the application for modification of an agreed paediatric investigation plan.
Published Dec 19, 2023
MHRA record cms.mhra.gov.uk

About MHRA paediatric investigation plans

A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.

Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date:

Browse all MHRA paediatric investigation plans